Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 234

The DOI matches its Crossref record.

The future of industrial bioprocessing: Batch or continuous?

Croughan, Matthew S., Konstantinov, Konstantin B., Cooney, Charles·2015·Biotechnology and Bioengineering

Abstract

For over 75 years, continuous bioprocessing has been investigated in both academia and industry as an alternative to batch bioprocessing. Many classic textbooks have major sections on continuous bioprocessing (e.g., Aiba et al., 1973; Bailey and Ollis, 1977; Blanch and Clark, 1996; Bungay et al., 1997; Shuler and Kargi, 2002; Wang et al., 1979; Yamane, 1995). Full of mass balances, kinetic expressions, and quantitative analysis of process alternatives such as cell recycle, these textbook sections make for both rigorous and interesting curriculum material. They often include equations for comparing the volumetric productivity of continuous versus batch bioprocessing. For most scenarios, such as when the cells are the intended product, continuous bioprocessing usually wins. One may then ask why many industrial firms still largely use batch rather than continuous bioprocessing. Excellent answers to this question have been provided by many of the same textbooks cited above. The following issues have been observed for continuous operations: (i) Lack of homogeneity in the continuous reactor vessel, including nutrient shortages or regions of cell accumulation, (ii) Challenges regarding long-term operability and maintenance of sterility, (iii) Poor short-term flexibility to handle multiple products, due to long run times, (iv) High cost and long times required for process development experiments using complex continuous culture systems in labs, and (v) Genetic instability of cells These observations point to scenarios wherein continuous bioprocessing makes sense, such as when it is desirable to have ongoing, evolution of a mixed population of cells, as in wastewater treatment, thus capable of consuming large volumes of variable feedstock year around. Another scenario wherein continuous bioprocessing makes sense arises when the product consists of optimal cell strain(s) that are highly evolved to grow under extreme conditions, such as Dunaliella salina, and thus there are few issues with contaminating organisms or genetic instability over long term culture in dedicated facilities. Other scenarios where continuous bioprocessing makes sense include production of unstable products, such as certain biopharmaceuticals, that would otherwise degrade upon incubation in batch culture. If a company already has process development platforms and manufacturing plants in place based upon continuous bioprocessing technology, it often makes sense to use these same platforms and plants for future projects, whether or not the products are unstable in batch culture. However, if a company already has manufacturing plants and process development platforms in place based upon batch culture technology, does it make sense for it to switch to continuous culture technology for stable products that can be successfully made in batch culture? The answer is clearly no. When recombinant CHO and hybridoma cell culture rapidly grew in the 1980's, several vendor firms marketed novel bioreactor systems for continuous perfusion cultures. These systems were tested by many product firms, such as Genentech, and found to have many of the same problems noted in paragraph two above. One pilot plant manager complained that “my definition of hell is a plant filled with those units”. Many product firms chose batch culture in stirred tanks for their standard platform. Some firms incorporated certain semi-continuous aspects into their batch systems, such as “repeated batch” (Yamane, 1995) approaches to seed trains, inoculum trains, and/or production cultures. Some firms now perfuse medium through production cultures, using an ultrafiltration membrane that retains the product in the bioreactor. Like the more traditional fed-batch approach, this is a variant of the batch approach, as the product is typically still harvested only once at the end of the culture. Back in the 1980's and 1990's, biopharmaceutical firms with unstable products had no choice but to work through the problems with continuous perfusion cultures. Some other firms, even with stable products, simply chose to start with continuous perfusion, and also worked through the problems. Some plant start-ups took over 20 tries at scale before achieving one fully successful, complete continuous perfusion run. Many firms that started with continuous perfusion to make stable products for early clinical trials eventually switched to batch for their late trials and commercial production. Early-stage process development and clinical manufacturing are often on the critical path to get a new product into clinical trials. Clinical delays due to process development or manufacturing issues can be very costly (including career wise!). Standard fed-batch culture services are offered by many biopharmaceutical contract manufacturers. Perfusion culture services are far less common and, even when found, are readily available only with the particular cell retention method already in use by that vendor. The compatibility o

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/bit.25529

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Croughan, M. S., Konstantinov, K. B., & Cooney, C.
Venue
Biotechnology and Bioengineering
Publisher
Wiley
Published
2015-02-18
Volume
112
Issue
4
Pages
648-651
ISSN
  • 0006-3592 (ISSN-L)
  • 1097-0290
OpenAlex
W2149717386
Cited by
234
References
0
FWCI
12.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.